290 related articles for article (PubMed ID: 12453338)
1. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
[TBL] [Abstract][Full Text] [Related]
4. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
5. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.
von Delius S; Eckel F; Wagenpfeil S; Mayr M; Stock K; Kullmann F; Obermeier F; Erdmann J; Schmelz R; Quasthoff S; Adelsberger H; Bredenkamp R; Schmid RM; Lersch C
Invest New Drugs; 2007 Apr; 25(2):173-80. PubMed ID: 16983507
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-safety profile: neurotoxicity.
Grothey A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
8. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.
Ali BH
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):272-9. PubMed ID: 20050845
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
12. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
13. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
Kurniali PC; Luo LG; Weitberg AB
Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
16. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
17. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
[TBL] [Abstract][Full Text] [Related]
18. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
Gent P; Massey K
Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
[TBL] [Abstract][Full Text] [Related]
19. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
